A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma

Inclusion Criteria: 1. Histologically documented squamous cell carcinoma of the thoracic esophagus; undergoing radical esophagectomy; the pathological stage is T(primary tumor)1-4 N(regional lymph nodes)1-3 M(distant metastasis)0 (ESOPHAGUS, Union for International Cancer Control(UICC) 2010) ; 2. Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy); 3. The expectation of life is more than 6 months; 4. Age: 18\~70 years old; 5. Normal hemodynamic indices before the recruitment (including white blood cell count\>4.0×109/L, neutrophil count\>1.5×109/L, platelet count \>100×109/L, hemoglobin≥90g/l, normal liver/kidney function); 6. ECOG (Eastern Cooperative Oncology Group) : 0-1; 7. Able to understand this study and have signed informed consent. Exclusion Criteria: 1. Have been treated with chemotherapy, radiotherapy and other anti tumor treatment except surgery; 2. Known or suspected of allergy to paclitaxel or carboplatin; 3. Female in pregnancy or lactating; 4. With significant psychological, family, social and other factors which may affect the ability to understand and sign the informed consent; 5. Patients with peripheral neuropathy(CTC grade≥2); 6. With other malignant tumors before the recruitment. 7. The researchers consider that the patient is not appropriate to enroll the study; 8. The patient can't be tolerant to postoperative adjuvant radiotherapy and chemotherapy for serious heart/lung/liver/kidney function, the haematopoietic system diseases, the immune system diseases, the nervous system diseases, cachexia and so on.